window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

schizophrenia treatment

  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Therapeutic Areas

    Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy

    Click Therapeutics has secured a $50M Series D investment from [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Newron publishes data showing clinically meaningful benefits of evenamide in treatment-resistant schizophrenia

    Newron Pharmaceuticals has published peer-reviewed clinical data demonstrating that evenamide, [...]

    May 5, 2026
  • Biotech & Pharma Business,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gedeon Richter UK takes over Reagila marketing and distribution rights in the UK

    Gedeon Richter UK has taken over full marketing and distribution [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Olorofim meets primary endpoint in phase 3 OASIS aspergillosis study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Spot Biosystems reports early clinical evidence for non-viral dystrophin delivery in Duchenne muscular dystrophy
    Categories: Advanced Therapies, Drug Discovery & Development
  • Neurizon strengthens manufacturing base with Elanco supply deal for ALS asset
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top